| Old Articles: <Older 44601-44610 Newer> |
|---|
 |
The Motley Fool
October 8, 2010
Anders Bylund |
Intrepid Potash Shares Popped: What You Need to Know Intrepid Potash is trading 10% higher today, after a government report revealed weak American corn crops this year.   |
The Motley Fool
October 8, 2010
Matt Koppenheffer s |
Kulicke & Soffa Shares Plunged: What You Need to Know The shares slipped 11% in intraday trading when the company announced that revenue for the fourth quarter would be "significantly below" revenue in the September quarter. |
The Motley Fool
October 8, 2010
Brian D. Pacampara |
Quantum Popped: What You Need to Know While investors should take analyst opinions with a grain of salt, Quantum certainly feels cheap. |
The Motley Fool
October 8, 2010
Rick Aristotle Munarriz |
7 Reasons to Worry About Next Week Let's go over a few of the names that are expected to go the wrong way on the bottom line next week: KMG Chemical... Oil-Dri... Bladex... Spartan Stores... WD-40... Cubist Pharmaceuticals... Valmont Industries... |
The Motley Fool
October 8, 2010
Anders Bylund |
TeleCommunication Systems Shares Popped: What You Need to Know This could be the beginning of a fine turnaround story. |
The Motley Fool
October 8, 2010
Rick Aristotle Munarriz |
This Week's 5 Dumbest Stock Moves Companies like Cisco, Qualcomm, Microsoft, Verizon, and others may be guilty of stupidity this week. |
The Motley Fool
October 8, 2010
Rick Aristotle Munarriz |
This Week's 5 Smartest Stock Moves There's always time to look at the bright side of life. |
The Motley Fool
October 8, 2010
Jeremy Phillips |
Should You Sell Energy Conversion Devices Right Now? We're seeking danger signs among this beloved stock. |
The Motley Fool
October 8, 2010
Jason Moser |
This Stock Has the Edge Porter's Five Forces examines a company through five lenses: barriers to entry, threat of substitutes, power of buyers, power of suppliers, and industry jockeying. Let's see how Netflix does with these measures. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
| <Older 44601-44610 Newer> Return to current articles. |
